Medinol (NIR stents)
РУ / EN
Since its founding in 1992 by Drs. Judith Richter and Jacob (Coby) Richter, Medinol has been at the forefront of developing new technologies for stenting systems (for cardiovascular interventions).
Backed by more than 400 patents, the company has delivered more than 2 million stents to date, and its advanced cardiovascular intervention technology continues to demonstrate outstanding clinical results.
The company is privately held and all of its operations, including research, development, quality control, regulatory affairs, clinical trials, manufacturing, marketing and sales, are conducted in-house.
The NIR stent was first introduced in 1996 and revolutionized interventional cardiology. It was the first stent to provide both flexibility and frame strength, allowing treatment of longer lesions with more complex anatomy.
This breakthrough greatly expanded the base of patients suitable for stenting and made this treatment method preferable to riskier, more complex and costly surgery.
NIR stents are among the most clinically studied bare metal stents ever produced. Since 1995, they have been studied in more than 25 clinical trials involving more than 5,000 patients.
Founders
Dr. Judith Richter
An experienced entrepreneur and one of the most prominent business leaders in the Israeli industry.
Along with Medinol, Dr. Richter is a co-founder and active board member of several private medical device companies specializing in new device development and medical innovation.
She is also a member of the board of directors of Mobileye NV, a company listed on the New York Stock Exchange. Previously, Dr. Richter founded and served as CEO of Medcon Ltd. a global provider of web-based cardiac imaging and information management technologies. She also served on the boards of several Israeli corporations, including Bezeq Ltd. and held an executive position at Teva Pharmaceutical Industries Ltd. one of the largest pharmaceutical companies in the world.
Dr. Richter successfully managed the business until it was acquired by McKesson in 2005.
Judith's extensive industry experience was preceded by her academic career - for over 10 years she was a lecturer at Tel Aviv University's Graduate School of Business, where she specialized in corporate strategy and decision making under uncertainty.
Today, Judith Richter is a member of the Executive Committee of the Hebrew University of Jerusalem, recipient of the 2013 Ramnichanu Prize in Economics awarded by Tel Aviv University in recognition of her exceptional contribution to Israel's economic, industrial and technological development. She has also been an honorary member of the Hebrew University of Jerusalem since 2013, from which she graduated.
Judith Richter holds a doctorate and a master's degree in organizational psychology from Boston University.
Dr. Kobi Richter
Dr. Jacob (Coby) Richter was the Company's Chief Technology Officer and headed Medinol's research and development, manufacturing, quality control and regulatory departments.
Prior to founding Medinol in 1992, Dr. Richter co-founded Orbotech, a leading microelectronics company listed on NASDAQ. He was the company's Head of Product Development and then Director of Marketing and Product Development. Dr. Richter is currently a member of Orbotech's Board of Directors.
In addition, Jacob has been a research scientist in the Artificial Intelligence Laboratory and Brain Research Unit at MIT, and was Head of Research and Development at the Israeli Air Force.
Jacob Richter holds a PhD in physiology and pharmacology from Tel Aviv University.
He currently serves on the cardiology board of Columbia University Medical Center and on the advisory board of the Center for Brain, Mind, and Machines at the McGovern Institute for Brain Research in the Department of Brain and Cognitive Sciences at MIT.
To date, more than 2 million Medinol stents have been delivered.
1996
Introduced NIR, the first coronary stent with superior flexibility and stability.
2000
Introduced NIR Elite with improved delivery and compatibility.
2002
Introduced NIRflex in a new design for an exceptional balance between fit and frame comfort.
2008
Introduced PioNIR in CoCr alloy with thinner struts and improved crossmember profile.
2014
Introduced NIRxcell, which with Flexx2 technology offers unrivaled flexibility, ease of movement and ease of delivery.
2017
Introduced EluNIR, the first drug-eluting elastomeric stent.
2022
EluNIR-Perl with enhanced deliverability is introduced.
2026
IoNIR, a revolutionary hybrid stent, is planned for launch.
More products of Israeli labor in the Telegram channel @madebyil.